As a diagnostic marker, CD133 is widely used for stratifying and assessing cancer patients, particularly in brain, colon, and prostate cancers, where it has demonstrated good prognostic value [45, 46, 47, 48, 49]. The gene discussed is PROM1; the disease is prostate carcinoma.